The limited response rate of cancer patients treated with dendritic cell (DC)-based vaccines indicates that vast improvements remain necessary. In many murine tumour models it has been demonstrated that the use of innate triggers (e.g. TLR triggers) in the maturation of DC results in higher efficacy. However, as few of these innate triggers are generated clinical grade, there remains a great necessity to fill the gap between fundamental mouse studies and a clinical trial in humans. In the present study we used a TLR2/4-agonist (FMKp which is available clinical grade) in combination with IFN-y (FIcocktail) in the maturation of elutriated monocyte-derived DC and compared it with the most used DC in current clinical trials (TNF -a/PGE-2, i.e, TP-cocktail). In addition to the assessment of CD4+ T cell polarizing capacity, we compared the quantity and intrinsic quality of induced CD8+ T cells of 2 different DC maturation protocols with all cells from the same donor. Besides differences in the cytokine profile, which could be coupled to increased Thl and Th17 polarization, we demonstrate in this study that FMKp/IFN-y matured DC are twice as effective in inducing cytotoxic T cells against known tumor antigens. Both DCs induced phenotypically equivalent effector memory CD8+ T cells that did not show a significant difference in their intrinsic capacity to kill tumor cells. These findings point to the therapeutic applicability of FI-DC as superior inducers of functional antigen-specific T cells. Their increased chemokine secretion is suggestive of a mechanism by which these DC may compensate for the limited migration observed for all ex vivo cultured DC when applied in patients.
Dendritic cells (DC) are very efficient initiators of potent immune responses in vivo. These cells are therefore attractive tools for cellular immunotherapy in the treatment of cancer and viral infections that evade the regular immune surveillance (1-3). As a consequence, a range of methods to generate large amounts of DC ex vivo has become available. They can be generated from a variety of sources, but DC differentiation from monocytes with a growth factor cocktail containing IL-4 and GM-CSF is the current gold standard (4) (5) .
Translating these culture methods into good manufacturing practice guidelines has allowed the introduction of DC immunotherapy into the clinic. Early DC vaccination studies proved to be feasible and non-toxic (6) , proof of principle studies demonstrated that DC loaded with tumour antigens can induce immune responses (7) (8) . However, the limited rate of tumour regression in clinical trials has indicated that mounting clinically effective immune responses using ex vivo-generated DC is difficult (9) . Among the causative factors for this limited response is definitely our limited understanding of the molecular signals driving effective T cell responses without simultaneous induction of suppressive T cells.
Since DC can easily be manipulated in vitro, most efforts have been invested in finding a relation between DC maturation and T cell stimulation (10) . The multitude of maturation cocktails used for superior vaccination design illustrates that the optimal stimulatory signal remains to be established. The most often used DC maturation cocktail in current applications includes TNF-a and PGE-2 with or without IL-l f3 and IL-6 (11) . Although this cocktail generated fully mature DC that are able to induce antigen-specific T cells and show migratory behaviour in vitro, it has become clear that this cocktail is far from optimal (12) . One of the most important disadvantages is the limited ability to mount potent Th 1 responses illustrated by the lack ofIL-12 production, which presumably results from the use of PGE-2 that is added to stimulate DC migration (13) (14) (15) (16) . Many maturation cocktails have been proposed as alternative. One attractive option involves the use of microbial ligands and Toll-like receptor (TLR) agonists in particular (17) . The TLR2/4 agonist FMKp in combination with IFN-y has been shown to exert powerful DC activation signals leading to high IL-12 secretion, Th1 skewing and cytotoxic T cell induction (18) (19) . Numerous studies have pointed towards the necessity of PRR triggering (TLR stimuli in particular) in DC maturation to obtain potent T cell responses, and this was correlated with potent anti-tumour responses in animal models (20) (21) (22) (23) . However, in the field of DC vaccination there is a big necessity to fill the gap between fundamental studies and a clinically approved trial. One tool which is available to fill the gap is performing in vitro experiments with primary human cells. These human studies are of particular relevance for the study of TLR ligands as discrepancies in TLR expression and function between species have been reported (24) . To date, only few Toll like receptor triggering agents have been generated according to good manufacturing regulations (GMP) allowing their use in the clinic. In addition it also remains to be established how the induction of antigen-specific T cells is influenced by these ligands.
Few studies companng differential DC maturation focus on CD8+ T cell heterogeneity (25) (26) . In analogy with CD4+ T cell subsets also functionally different CD8+ T cell subsets exist which exert opposite effects on T cell polarization in vivo (27) (28) . These CD8+ subsets were designated Tel secreting IFN-y and Tc2 secreting IL-4 (29) (30) . In addition, CD8+ T cells can differentiate upon antigen recognition into either central (TeM) or effector memory (TEM) T cells. The factors that drive CD8+ T cells into these different phenotypes remain to be determined but the quantity and quality of stimulation by the DC and cytokines have been suggested as contributors (31) .
At present it remains unclear whether differential DC maturation can be exploited to generate different subsets of CD8+ T cells. To this end, we made a direct comparison of 2 clinically relevant DC maturation cocktails from the same DC preparation. The first cocktail consisted of a clinical grade preparation of membrane fragments of Klebsiella pneumoniae (FMKp) in combination with IFNy (FI-cocktail), whereas the second cocktail was composed of TNF-a and prostaglandin-E2 (PGE-2) (TNF-a/PGE-2, i.e. TP-cocktail), which is most often used in current DC vaccination trials. These DC were compared according to their phenotype, migratory behaviour and cytokine secretion which was correlated to their T helper cell polarization and their differential ability to induce cytotoxic T cells. The data provide insight into DC-regulated control of Thl/Th17 vs Th2 polarization, and CTL phenotype and functionality, and establish PI-DC as powerful inducers of antigen-specific T cells.
MATERIALS AND METHODS

Dendritic cells
Immature Des (immDC) were generated by ImmunoDesignedMolecules (Paris, France) from 5 HLA-A2+ leucopheresis products as previously described (17, 32) and frozen at 20 x 10 6 cells per vial in 1.5 ml Iscove's modified Dulbecco's medium (Invitrogen Ltd., Paisley, UK) + 50% human serum (HS, Sanquin blood bank, Maastricht, The Netherlands) + 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich Co., St. Louis, MO, USA). As partners in a joint EU project, we obtained immDC from IDM. Upon thawing, cells were left to recover in serumfree AIM-V containing differentiation cytokines.
The following two days immDC were matured using one of two maturation cocktails. The TP-maturation cocktail consisted of AIM-V with IL-4 (500 U/ml; Strathmann Biotech AG, Hannover, Germany), GM-CSF (400 U/ml; Berlex, Richmond, CA, USA), TNF-a (1000 U/ml; Biosource, Camarillo, CA, USA) and PGE-2 (18 ug/ml Sigma) (33) . The Fl-cocktail contained IL-13 (50 ng/ml; Biosource, Camarillo, CA, USA), GM-CSF (500 U/ml), IFN-y (500 U/ml; Strathmann Biotech AG) and a TLR2/4 agonist (1 ug/ml) (17) . As agonist, a GMP-grade lysate of Klebsiella pneumoniae was used (Pierre Fabre institute, Boulogne, France). This preparation contains membrane fractions (including the TLR2 ligand outer membrane protein A OmpA (34» and proteoglycans (including the TLR4 ligand LPS) from Klebsiella pneumoniae.
Scanning electron microscopy
Glass coverslips (Miles Scientific, Naperville, IL, USA) were cut, transferred to a 24-well plate and coated for I h with 50 ug/ml fibronectin (Roche Diagnostics GmbH, Mannhein, Germany). After washing the coverslips, ImmDC were allowed to adhere and mature in cocktail-containing medium for 3 h, followed by two PBS washes. Coverslips were fixed in 2.5% glutaraldehydel PO4 for 10 mins, washed twice with PBS and analysed with a XL30TMP microscope (FEI company, Eindhoven, the Netherlands).
Flowcytometry
All antibodies for flow cytometry were obtained from BD Pharmingen (BD Biosciences, Erembodegem, Belgium) except anti-CCR-7 (R&D Systems, Minneapolis,MN, USA) andanti-Foxp3 (eBioscience,SanDiego,CA, USA). MUC1 13 • 21 and MART-1 2 6-35 specific HLA-A*0201+ dextramers were purchased from Dako Cytomation (Glostrup, Denmark). Antibodies were used as either Fluorescein isothiocyanate (FITC), Pycoerytherin (PE), PE-Cy7, Peridinin chlorophyll protein (PER-CP) or allophycocyanin (APC). All antibodies were incubated at the proper dilution for 30 mins at RT. Cells were fixed in 1% paraformaldehyde /PBS (PFA, Merck, Darmstadt, Germany). 7-AAD was used to exclude dead cells from analysesthat were all performedon a FACSCalibur (BD Biosciences).
Cytokine array
After 48 h maturation, cell-free supernatants of differentially matured DC (10 6 cells/ml) were harvested. Undiluted supernatants were analysed on human cytokine antibody arrays VI-VIII (RayBiotech, Norcross, GA, USA) according to the manufacturer's instructions. After development, blots were photographed with a LAS-. 3000 imaging system (Fujifilm, Sint-Niklaas, Belgium). The spots were quantitated using AIDA Array Analysis Software (ImaGenes, Berlin, Germany). Quantitated chemiluminescence values of individual spots were normalized to the mean of 6 positive control spots after background (mean of4 negative control spots) subtraction using the RayBio Human Cytokine Antibody Array C Series 2000 Analysis Tool (RayBiotech).
Cytokine secretion
Quantification ofIL-5, IL-6, IL-IO, IL-12, IL-17, TNFa, IFN-y TGF-~I and CCL-19 in culture supernatants was performed using the respective ELISA kits obtained from Pierce Endogen (Rockford, IL, USA), R&D Systems, and Sanquin (Amsterdam, The Netherlands), and conducted according to the manufacturer's instructions. Absorbance was measured at 450 nm using a microtiterplate reader (BioRad, Hercules, CA, USA). Intracellular IFN-y and IL-4 production of antigenspecific T cells was determined after co-culture with peptide pulsed T2 cells for 4 h at 37°C in the presence of I ug/ml Brefeldin A (BD Biosciences). After staining the extracellular antigens CD3 and CD8, cells were fixed and permeabilized using the Fix&Perm kit from Caltag Laboratories (Burlingame, CA, USA) followed by addition of anti-human IFN-y and IL-4 (BD Biosciences) antibodies and incubation for IS minutes at RT. Cells were fixed in 1% PFAlPBS and analyzed by flowcytometry.
Migration assay
Migration of matured DC towards chemoattractants was measured using Transwell" plates (Coming Costar, New York, NY, USA). The lower cabinet was filled with 600 III AIM-V containing 250 ng/ml CCL-19 or-21 (R&D Systems, Minneapolis, MN, USA). Triplicate inserts were filled with 100 III 10 6 DC/ml, and migration proceeded for 4 h at 37°C I 5% CO 2 , The migrated cells were collected from the lower compartment and counted using the Z I™ Coulter Counter (Beckman Coulter, Fullerton, CA, USA). To calculate the percentage of migrated cells, the total number of migrated DC was divided by the total number of DC in the upper well after subtraction of the mean number of spontaneously migrated DC.
Priming culture
T cells were isolated from 9 X 10 8 PBMCs of the same leucopheresis product by binding them to fixed sheep red blood ceIls (SRBC). After density centrifugation, SRBC were removed from the TceIl fraction by lysis in NH 4C1 and KHC0 3 • DC were pulsed in AIM-V for 2 h with 40 ug/ml MUCI 13 _ 21 peptide (LLLTVLTVV; NeoMPS, Strassbourg, France) or40 ug/ml MART-I 26-35 peptide (ELAGIGILTV; NeoMPS) together with 5 ug/ml~2 microglobulin and 50 ug/ml PADRE (AGVAAWTLKAAA). Subsequently, 24xlO 6 T ceIls were stimulated with Zxl Ovpeptide pulsed mDC in AIM-V containing 10 ng/ml IL-7 (Biosource, Camarillo, CA, USA). After 7 days, T ceIls were harvested, counted and restimulated with 2x 10 6 pulsed mDC (20 Ilgi ml MUC1 13_21 or 20 ug/ml MART-1 26_35 with I ug/rnl~2 microglobulin) in 24 ml AIM-V supplemented with 20 Ulml IL-2 (Proleukin, Chiron Benelux BV, Amsterdam, The Netherlands). Medium with cytokines was refreshed every other day. On day 12 of the priming culture, T ceIls were coIlected and stained with CD8-PE and APClabeled MUC 1 13 _ 21 or MART-1 26_35 dextramers (Dako Cytomation) for I h at RT. CeIl suspensions were filtered through MACS pre-separation filters (Miltenyi, Utrecht, the Netherlands) and CD8+/dextramer+ ceIls were sorted with the FACSAria (BD Biosciences). Sorted ceIls were cultured for 7 days in presence of phytohaemagglutinin (0.2 ug/rnl) and IL-2 (40 U/ml) on feeder mix consisting of irradiated (80 Gy) PBMCs and lY ceIls. Viability was determined by trypan blue exclusion.
"Cr-Release assay
The ability of sorted T-ceIls to kiIl target ceIls was assayed using a standard chromium release assay. In short, antigen-specific T ceIls were incubated for 4 h at 37°C I 5% CO 2 with 10 4 target ceIls, at an E:T ratio of20: I. As target ceIls we used T2 (Tapll2-deficient) and MUCI positive tumor ceIl lines (MCF7, breast cancer; OVCAR-3, ovarian cancer and RPM18226, multiple myeloma) were labeled with 75 IlCi 5lCr-sodiumchromate/I0 6 ceIls (Amersham Life Sciences, Buckinghamshire, England). Target ceIls alone were used as negative control (spontaneous release) and target ceIls in the presence of 10% SDS (Bio-Rad Laboratories, Hercules, USA) as positive control (maximal release). Supernatants were coIlected and analyzed with a gamma counter. Specific kiIl was calculated as:
Statistical analysis
To compare the percentages of antigen-specific T ceIls by both DC (T+TP-DC and T+FI-DC, respectively), we normalised values to the percentages observed with TP-DC (100%). The normalised percentage ofT+FI-DC was compared with this 100% value using the non-parametric Wilcoxon signed rank test. Cytokine secretion between ceIl populations was compared with paired T-tests. P-values are given.
RESULTS
Dendritic cell phenotype and cytokine production after 48-hour maturation
For all experiments aliquots of immDC were thawed and matured with either the TP-cocktail or the PI-cocktail (see M&M). Fig. lA shows representative scanning electron micrographs ofboth types of mature DC (mDC) (n>20). TP-DC exhibit a stellate morphology with long, unbranched dendrites whereas FI-DC display a more elongated appearance with fewer but more branched processes.
To evaluate the phenotype of both differently matured DC, we assessed by means of flow cytometry the expression of MHC class I and class II molecules (HLA-A2 and HLA-DR, respectively), costimulatory molecules (CD 80, CD83, CD86 and CD40), CDla, which is involved in presentation of non-peptide antigens, and CD 11 c characteristic integrin a DC. Both mature DC populations showed an upregulation of HLA-DR, CD80, CD83, CD86, and CD 11 c as compared to immature DC (data not shown). When comparing the expression levels of maturation markers between TP-DC and PI-DC ( Fig.  1B) , we reproducibly noted a higher expression level of CD80 by PI-DC. Furthermore, we reproducibly (n=5) observed a slight upregulation of CD83 upon maturation, which was more pronounced in TP-DC ( Fig. IB) . No differences were seen in the expression levels ofHLA-A2, HLA-DR, CD86, CD40, CDllc and CD 1a between the two DC populations, which was also reproducible.
Because DC-derived cytokines are considered key regulators in directing immune responses, we decided to screen whether both DC differ in their production of cytokines, therefore, a semi-quantitive antibody array analyzing 174 cytokines simultaneously was performed (Fig. 1C ). Quantitated chemiluminescence values of individual protein spots were normalized to the intensity of control spots (100% value) after background (0% value) subtraction. This normalized protein expression is plotted for differently matured DC in an XIY graph. The threshold for upregulation was set on 1.5. Eighty-six cytokines have spot intensities below the threshold (grey box in amounts. Forty-seven out of 174 soluble factors have higher (> 1.5 fold) spot intensities in the supernatant of FI-OC, whereas only 8 are found at higher levels in the supernatant of TP-OC. The identity of the differentially secreted protein factors and their fold increase in relative spot intensity are listed in Table I . For 7 cyto-and chemokines we confirmed upregulation with ELISA (4 of which are shown in Fig. 10 (IL-6, IL-12, IL-IO and TNF-a) and CCL-5, CXCL-IO and IL-4 (data not shown). In all cases the difference could be confirmed in more donors. Furthermore, the fold difference in spot intensity appeared to be an underestimation of the true fold difference in protein secretion when measured with ELISA in all cases (n=7). Among the factors found to be upregulated, several cytokines used in the maturation were identified. Indeed, IL-13, IL-4 and GM-CSF are among the brightest spots detectable since they are added in high concentrations to the supernatant. Importantly, TNF-a is not exclusively found in TP-OC (present in the maturation cocktail), but is actively produced by FI-OC ( Fig. 10 ). To assess whether TP-OC are also able to produce TNF-a, the maturation cocktail was washed away after 6 h and the potential production between 6 and 48 h was analysed. In contrast to the supernatant of washed FI-DC, no TNF-a was found in the supernatant of washed TP-DC. Besides TNF-a, FI-DC produce several cytokines involved in DC maturation (IL-l 13, TNF-u and IL-6), suggesting an autocrine maturation process. However, the most striking difference was a group of 15 chemokines (bold in Table I ) that potentially attract other immune cells and a number of cytokines involved in T cell polarization (IL-6, IL-I0, and IL-12) and T cell support (IL-7 and IL-15) that were found in higher quantities in the supernatant ofFI-DC as compared to TP-DC.
To study T cell polarizing cytokines quantitatively, these cytokines were measured in DC supernatants (48h of maturation) by ELISA. As shown in Fig. ------CCR7 ------ID, FI-DC show higher IL-12, IL-I0, IL-6 and TNF-a (when DC were washed at 6 h) production as compared to TP-DC. Both DC secrete low levels of the Treg inducing cytokine, TGF-J3.
Effect of the maturation cocktail on the migratory program ofDC
For DC to migrate they have to be equipped with the appropriate set of chemokine receptors, whose expression is reprogrammed during the maturation process. To investigate the influence of both maturation cocktails on the chemokine receptor expression, we analyzed CCR6 and CCR7 expression. Both TP-and FI-DC express low but reproducible levels of CCR7 ( Fig. 2A ), but no CCR6 (not shown) after 48 h of maturation. Because CCR-7 is the key chemokine receptor regulating traffic of DC to the lymph node, we compared their migratory behavior towards the CCR-7 ligands; CCL-19 and CCL-21 in transwell assays. To exclude the possibility that both maturation cocktails induce migration with different kinetics, we followed their migration at different time-points after maturation. ImmDC were CCR7 negative (data not shown), and did not migrate towards the chemokine gradient. TP-DC showed an increased migration through the transwell upon maturation while FI-DC did not migrate at any time-point (Fig. 2B ).
T H cell induction by DC cultured with different maturation cocktails
The combination of cytokines present during the priming of naive T cells by DC influences their polarization. Since TP-and FI-DC display different cytokine profiles including polarizing cytokines, both DC were pulsed with class I-restricted peptides and a pan-HLA-DR binding peptide (PADRE) and were used to prime autologous T cells. To analyze whether both DC differ in their CD4+ T cell polarizing capacity the cytokine profile of T cell cultures stimulated with both DC after 7 days was compared. IL-5 secretion was only observable in coculture experiments with TP-DC (in 4/5) and not in cocultures with FI-DC. This suggests at least some Th2 polarization was induced by the former DC (Fig. 3A) , which is supported by our observation of a small but reproducible percentage of CRTH2+ CD4+ cells only identified when stimulated with 68 FI -DC . . .. TP-DC ( Fig. 3B ). CRTH2 is the prostaglandin D2 receptor and is considered the best surface marker for the selective staining of Th2 cells (35) . T cells stimulated with PI-DC, on the other hand, produce more IFN-y (in 4/5), suggesting stronger Thl polarization induced by these De. This is supported by the observation of a higher percentage of CD4+ T cells with a high expression of CXCR3 which is characteristic for Thl polarized cells but is not as specific as CRTH2 for Th2 cells (data not shown).
Maturat ion time (hours)
To determine if both DC induce Thl7 cells, we examined whether IL-17 was produced. In the supernatant ofT cells stimulated with PI-DC, higher quantities of IL-17 were found (Fig. 3A) , indicating that these DC are more capable of inducing Th17 cells. Suppressive cytokines such as TGF-B and IL-10 were found in comparable amounts in both T cell cultures (Fig. 3A) .
As DC can induce Tregs in vitro, we compared a possible Treg induction by both DC populations by FACS analysis. CD4+ Tregs are characterized by a high expression of CD25 and they express the transcription factor FOXp3, which is required for their regulatory function (36) . On day 0, very low numbers of Tregs (CD25 and FOXp3 double positive cells) «0.05%) were observed. Both DC are capable of inducing Tregs, as approximately I% of CD4+ T cells were also Foxp.I' seven days after the first stimulation with peptide-pulsed DC (Fig. 3C ). No consistent difference in Treg induction could be found between TP-and PI-De.
FI-DC induce more antigen-specific T cells as compared to TP-DC
To compare the induction of tumour antigenspecific T cells, both mDC were pulsed with HLA-A2-restricted immunodominant epitopes of the tumour-associated antigens (TAA) mucin-I (MUCI 13 _ 2 ) or Mart-I / Melan-A (MART-I26-35) and a pan-DR binding peptide (PADRE). Fig. 4A shows the average cell numbers during T cell stimulation assays and no increase in total T cell number was observed during the initial priming with either mDe. Upon restimulation, a strong proliferative response was observed in both conditions, but no significant difference in the absolute T cell numbers was measured.
To assess whether both mDC differed in their capacity to induce antigen-specific T cells, we quantified the number of antigen-specific CD8+ cells by dextramer staining on various days. In all individuals tested we observed a higher starting frequency of MART-l 26.J5-specific T cells compared to MUC lI3.21-specific T cells. Possibly, for this reason, higher numbers of MART-l 26.35-specific T cells were obtained throughout the stimulation assays. Fig. 4B shows dextramer stainings of T cells after 2 stimulations. Although there was no difference in the overall proliferative response with either DC, there was a difference in the percentage, and the absolute numbers, of antigen-specific T cells generated. After the first stimulation (day 7), significantly more antigen-specific T cells were observed when stimulation was performed with Fl-OC than with TP-DC (Fig. 4C ). In 6/7 experiments, more than double the absolute number of antigenspecific T cells after one stimulation was seen. After the second stimulation there was still a significant difference, and a 2-fold increase was found in 5/7 experiments (Fig. 4C ). 
Both DC induce effector memory antigen-specific T
. Phenotypic characterization ofantigen-specific CD8+ T cells. A) CD45RO. CCR7 and CXCR3 staining ofT cells on day 11. CD45RO and CCR7 are plotted against dextramers for antigen-specific T cells and were gated on CD8+ cells. CXCR3 was double stained with CD8. and gated on the living, low FSC/SSC cells. Left panels represent T cells stimulated with TP-DC and right panels represent T cells stimulated with FJ-De. B) Antigen-specific T cells were sorted at day 12from T cell stimulation assays. After 7 days ofrecovery on feeder cells in presence ofIL-2, cells were stained intracellularly for IL-4 (left panel) and IFN-y (right panel) after stimulation (5 h) with peptide-pulsed (grey histograms) or non-pulsed (open histograms) T2 cells. Cells were gated on CD3+ and CD8+. Isotype controls overlap with non-pulsed T2 cells (not shown). C) Fas and FasL expression ofantigen-specific T cells on day 12 of the T cell stimulation assay.
Cells were gated on CD3+ and CD8+. Stainings are representative ofat least 3 independent observations. cells with IFN-y but no IL-4 production As quantity and density of stimulation and the cytokine microenvironment may influence the fate of memory T cell differentiation, we analysed whether the different DC influenced CD8+ T cell specialization. CD8+, antigen-specific T cells generated with both DC stained positive for CD45RO and CXCR3 (Fig. 5A) , and negative for CD45RA (data not shown) and CCR7 (Fig. 5A ). This indicates that the generated antigen-specific T cells were of the TEM and not the TCM phenotype.
In addition to the TEM and TCM phenotype, antigen-experienced CD8+ T cells can be classified as TcI, Tc2 and TcO based on their cytokine secretion.
To determine the subtype, CD8 and dextramer double positive T cells were sorted from DC-T cell coculture experiments, incubated with peptideloaded T2 target cells and analyzed for cytokine expression. Upon antigen recognition, MUCI 13 _ 21specific T cells accumulated IFN-y intracellularly and no IL-4 accumulating T cells were found in any condition (Fig. 5B ). When MUC 13 _ 21 reactive T cells were stimulated with T2 cells loaded with an irrelevant (MART-1 26 _ 3s ) or no peptide, only a very small percentage of IFN-y accumulating cells was identified. This intracellular staining was confirmed by IL-4 and IFN-y ELISA (3 donors; data not shown). Similar data were observed when evaluating MART-1 26 _ 35 reactive T cells (data not shown). These data indicate that, despite the difference in cytokine secretion and in the induction of antigen-specific T cells, both DC induce antigen-specific TcI cells rather than Tc2 cells. One of the cytolytic mechanisms by which antigen-specific T cells can induce cell death in target cells involves the induction of FasL on the surface of cytotoxic T cells (37) . This bystander mechanism may account for high background killing in in vitro cytotoxicity assays. Therefore, FasL-expression was routinely checked on antigen-specific T cells. Prior to cell sorting and cytotoxicity assays, all specific T cells stained negative for FasL (Fig. SC) .
In some experiments when a third stimulation was performed, expression of FasL was observed on the majority of antigen-specific T cells (data not shown). This was associated with reduced viability of T cell cultures and high background killing of target cells (data not shown). In contrast to the regulation of FasL, all T cells retained a constitutive expression of Fas throughout the stimulation assay (Fig. SC) .
The intrinsic capacity ofMUCl 13 _ 21 reactive T cells to kill target cells is not influenced by differential DC maturation
To test whether differentially matured DC influence the functionality of antigen-specific T cells, we compared their capacity to kill target cells. To exclude possible regulation by the CD4+ and the CD8+ compartment, antigen-specific T cells were sorted based on 7-AAD-IFSC and gated on CD8+ I MUCI 13 _ 2 1 + cells. The second sorting gate and post-sort purity is shown in Fig. 6A . The minimal post sort purity was > 90%. After a recovery and expansion period, T cells were evaluated for their capacity to kill various target cell lines. As shown in Fig. 6B , MUCI 13 _ 2 1 pulsed T2 cells are killed by MUCI 13 • 21-specific T cells while unpulsed T2 cells or MART-1 26 _ 35 pulsed are not (data not shown). No differences in the amount of killing by T cells generated with either DC were seen. In addition, we showed, by studying lysis of MUCI expressing HLA-A2+ tumour cell lines, that these T cells are also able to recognize naturally presented MUCI. Consistent with previous reports, we did not see lysis of the ZR-75.I cell line (38) . All other cell lines displayed varying levels of lysis when incubated with MUC1 13 • 21 reactive T cells, indicating that the MUCI-specific T cells can recognize the MUC l-peptide presented by tumour cell lines in the context of HLA-A2 (Fig. 6C) .
Although there was considerable interexperimental variability regarding the percentage of lysis of these cell lines, we did not observe (within one experiment) consistent differences between T cells generated with differentially matured DC.
DISCUSSION
The successful clinical application ofDCs as anticancer therapies requires detailed understanding of the molecular events associated with DC maturation and their manipulation to optimise immune responses. Although many murine studies have shown that the concept of DC vaccination works, it cannot be directly translated into clinical practice (I). Therefore, it is of the utmost importance to translate the experimental work into clinically approved protocols in humans. To date human studies have shown only limited success (l0). To investigate how the use of toll-like receptor agonists influences the quality and quantity of antigen-specific CD8+ T cells in humans, clinical grade monocyte-derived DC were matured with IFN-y in combination with a membrane fraction ofKlebsiella pneumoniae containing TLR2/ 4 agonists (FMKp which is available clinical grade) (39) . Phenotypic characterisation combined with intracellular cytokine stainings showed no difference in the specific subset of cytotoxic T cells that was induced with these different DC. All antigenspecific CD8+ T cells are characterised as CCR7-, CD45RO+ and CXCR3+ T EM cells. Both DC induce predominantly antigen-specific CD8+ T cells with IFN-y but no IL-4 secretion, which is consistent with a TcI phenotype. This characterisation is further supported by the observation of activation-induced cell death in these cultures after a third stimulation, which was often associated with the induction of FasL on these T cells. Human Tel clones have been shown to display a higher susceptibility activation induced cell death as compared to Tc2 clones (29) . In addition, we observed no obvious difference in the killing capacity of sorted TAA-specific CD8+ T cells on the basis of equal cell numbers. This is supported by the observation that differentially matured DC induce TAA-specific T cells with similar avidity (40) . Taken together, these data indicate that the profound difference in cytokine profile of TP-and FI-DC does not influence the intrinsic quality of generated T cells as both DC induce phenotypically and functionally equivalent T cells. However, FI-DC usually induced twice as many TAA-specific CD8+ T cells as compared to TP-DC. Since this suggests that FI-DC will also induce a larger CTL response in patients, it is relevant to elucidate the causative mechanism.
The first mechanism why more antigen-specific T cells were observed with FI-DC may be due to the cytokine profile. It has been demonstrated that IL-12 not only affects the differentiation of TcI cells (30) but also stimulates their expansion. In addition to IL-12, also other factors implicated in homeostatic proliferation such as IL-7 and IL-15 (41) are produced in higher quantities by FI-DC. This indicates that in contrast to TP-DC, FI-DC are equipped with a cytokine profile which favours the rapid proliferation of CD8+ memory T cells.
A second possible contributing factor to the observed difference in T cell induction may be differential TH polarization by both DC. In the T cell stimulation assay CD4+ T cell activation was increased by the addition of a pan-HLA-DR binding peptide (PADRE), which is also proposed as adjuvant for vaccination trials (42) . We observed that PADRE facilitates mounting CD8+ T cell responses. However, by comparing surface markers differentially expressed by Th I and Th2 cells [CRTH2 and CXCR3; reviewed in (43) (44) ] and the cytokine profile of T cell cultures we show that PADRE does not replace the need of T cell polarization. Our observations of IL-5 secretion and CRTH2 positive CD4+ cells only in stimulation assays with TP-DC suggest that with these DC at least some Th2 polarization occurs. In contrast, the higher percentage of CXCR3+ CD4+ T cells upon stimulation with FI-DC together with a high IFN-y production is indicative of a more potent Th l skewing and the increased amount of IL-I 7 in these cultures indicates that there is also Thl7 polarization. These differences in T cell polarization are consistent with the cytokine profile of both DC. FI-DC produce more IL-12, favouring Th l polarization, and the high production of IL-6 and IL-I P production in combination with small amounts of TGF-pI (in contrast to TP-DC) has been shown to favor Thl7 differentiation (45) (46) . Increased Th I polarization has already been coupled with increased CD8+ T cell responses, but with regard to Thl7 induction it remains to be determined how they influence cytotoxic T cell induction. It also remains debatable whether the induction of Th17 cells is beneficial in cancer. Th 17 cells can contribute to tumor growth by stimulating tumor-associated inflammation, but are also suggested to induce anti-tumor responses via an IFN-y dependent mechanism (47) (48) .
DC have been shown to expand functional Tregs in vivo and the nature of the DC maturation stimulus has been shown to determine the efficacy of Treg induction in vitro (13) . Because PADRE has been proven to reverse chemotherapeuticum-induced immune suppression in vaccinated mice, it is relevant to study whether PADRE prevents Treg induction in humans. However, with both DC, a small but significant population of CD4+CD25+Foxp3+ T cells was observed 7 days after the first stimulation as compared to the starting population. Although Foxp3 was recently shown also to be transiently expressed by recently activated T cells (49) , it is unlikely that such cells are present 7 days after stimulation. At present, we are performing functional assays to study the consequences of Treg induction.
To mount an effective anti-tumour response, DC are required to interact with the appropriate lymphocytes in the draining lymph node. CCR7dependent trafficking to this anatomic location is considered essential for successful DC vaccines. Despite the difference in migratory potential of both DC in transwell studies, recent in vivo trafficking studies have shown that only 2-3-% of subcutaneously injected TP-DC traffic towards draining lymph nodes in melanoma patients (50) , which is comparable to nodal trafficking of FI-DC in multiple myeloma patients using a similar vaccination regimen (51). Therefore, it still remains to be determined whether differentially matured DC from one patient differ in their traffic to lymph nodes and whether in vitro assays predict migratory behaviour. Besides migration to lymph nodes, DC have to interact with appropriate lymphocytes, which are also chemokine driven. We show that differential maturation of DC results in large differences in chemokine secretion. PI-DC produce at least 15 chemokines in higher quantities as compared to TP-DC, including important T cell attracting chemokines such as CCL-19, CCL-5 and CXCL-l 0, which may ultimately lead to preferential attraction of different immune effector cells (Van Elssen et al., manuscript submitted). Taken together, we demonstrated that maturating DC with a combination of TLR-2/4 agonist (which is available clinical grade) + IFN-y induces stronger Thl/Th17 skewing and a two-fold higher number of antigen-specific TEM killer cells than TNF-a + PGE-2 matured DC. In addition, we show that FI-DC have a higher production of 15 chemokines, suggesting that these cells are more potent attractors of other immune cells when administered in vivo. Importantly, injection of peptide-loaded PI-DC alone has not been very successful in metastatic melanoma patients (52) . This does not preclude the use of PI-DC in the clinic but illustrates that for clinical success, other requirements than only DC quality such as tumor type, antigen selection and loading strategy, overriding immunosuppression, angiogenesis inhibition, among others, need to be manipulated. The present study demonstrates that TLR2/4 ligand + IFN-y matured DC are superior inducers of functional antigen-specific CD8+ T cells in comparison to the most often used DC in clinical trials. It can therefore be speculated that the induction of twice the number of antigen specific T cells by the same number of injected DC in vivo will result in a stronger anti-tumour response. Partly based on these results, a clinical trial is planned in multiple myeloma patients in which TLR2/4 + IFN-y matured DC will be directly compared to DC matured with the more conventional TNF-a + PGE-2 maturation.
